Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

Right Now

Multiple Sclerosis Drugs Market is Projected to Expand at a CAGR of ~6% During the Forecast Period 2019 - 2027

In terms of revenue, the global multiple sclerosis drugs market is projected to expand at a CAGR of ~6% during the forecast period, due to numerous factors, about which, TMR offers comprehensive insights and forecasts in the global multiple sclerosis drugs market report

Multiple sclerosis is a central nervous system disorder, and a potentially disabling disease of the spinal cord and brain. In multiple sclerosis, the immune system attacks the myelin (protective sheath) that shields the nerve fibers, which causes communication issues between the brain and the rest of the body. Multiple sclerosis can cause permanent deterioration or damage to the nerves. The cause of multiple sclerosis is still unknown. Researchers believe that, genetic and environmental factors contribute to the risk of developing multiple sclerosis. Rise in the prevalence and incidence of multiple sclerosis, rapid rise in the geriatric population leading a surge in population with multiple sclerosis, and increase in awareness about multiple sclerosis are major factors fueling the global multiple sclerosis drugs market.

Request a Sample of Multiple Sclerosis Drugs Market Report

    • Monoclonal Antibodies to Dominate Market

In terms of drug class, the global multiple sclerosis drugs market has been segmented into interferon-β, sphingosine 1 phosphate receptor modulators, mixed polymers, monoclonal antibodies, NF-κB inhibitors, pyrimidine synthesis inhibitors, and others. The inteferon-β segment accounted for a prominent share of the global multiple sclerosis drugs market in 2018. Inteferon-β is a cytokine in the interferon family that is used to treat multiple sclerosis. Inteferons are proteins produced by the human body. Inteferon-β drugs include Avonex, Betaseron, Extavia, Rebif, and Plegridy. However, the monoclonal antibodies segment is expected to dominate the global multiple sclerosis drugs market during the forecast period. Dominance of the segment is likely to be attributed to the launch of new monoclonal antibody products for the treatment of multiple sclerosis, including Ofatumumab and Ublituximab, during the forecast period.

    • Strategic Collaborations, Investments, and New Product Launches by Key Players to Drive Market

The report provides the profiles of leading players operating in the global multiple sclerosis drugs market. Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen Inc., Actelion Pharmaceuticals (Johnson & Johnson), and EMD Serono (Merck KGaA) are major players operating in the global multiple sclerosis drugs market.

Load More wait